Tumor News and Research

RSS

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.

8 Jan 2014

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Janssen-Cilag International NV today announced the early stopping of PCYC-1112-CA, the Phase 3 study of ibrutinib in the treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival as compared to the control, the primary endpoint of the study.

8 Jan 2014

Professor receives ALSF grant to develop cancer vaccine technology that help children to have healthy life

In 2004, a form of cancer known as neuroblastoma claimed the life of Alexandra (Alex) Scott, a little girl who gained national attention for using her lemonade stand to raise money for cancer research.

8 Jan 2014

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream - lethal invaders that are linked to almost all cancer deaths - by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

8 Jan 2014

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

Two research powerhouses, Loyola University Chicago and the University of Notre Dame, are joining forces in a multidisciplinary cancer research collaboration.

8 Jan 2014

Erythropoietin may promote cancer cell proliferation and survival

In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.

7 Jan 2014

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.

7 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Memorial Sloan-Kettering Cancer Center receives $90M in new financial support from Ludwig

Memorial Sloan-Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Announced today, the gift is among the largest publicly recorded gifts to cancer research made by a private organization, bringing the total funding to date for Ludwig Centers and endowed professorships at the six institutions to $900 million.

7 Jan 2014

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.

7 Jan 2014

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice University's Baker Institute for Public Policy and the University of Texas MD Anderson Cancer Center.

7 Jan 2014

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

7 Jan 2014

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Research from the National Institute of Respiratory Diseases informs that besides smoking, there are other factors associated to the development of lung cancer such as the smoke from burning lumber and coal, as well as pollutant particles.

7 Jan 2014

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

Cancer researchers at the University of Chicago and five other leading institutions will share equally in a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Ludwig Cancer Research is an international community of researchers dedicated to pursuing life-changing discoveries to alter the course of cancer.

7 Jan 2014

MD Anderson, Pfizer to advance development of immune-based treatment for cancer

The University of Texas MD Anderson Cancer Center and Pfizer will collaborate in the development of immune-based approaches to cancer treatment, the first such agreement made through MD Anderson's Moon Shots Program immunotherapy platform.

6 Jan 2014

MIT receives $90M from Ludwig Cancer Research to strengthen interdisciplinary approach to cancer research

MIT has received $90 million from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, a gift that aims to transform basic research on metastasis, the process by which cancer cells spread from a primary tumor to distant sites in the body.

6 Jan 2014

Tumor News and Research

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Professor receives ALSF grant to develop cancer vaccine technology that help children to have healthy life

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Research opens door to new direction of PAH treatment

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

Erythropoietin may promote cancer cell proliferation and survival

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Memorial Sloan-Kettering Cancer Center receives $90M in new financial support from Ludwig

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

MD Anderson, Pfizer to advance development of immune-based treatment for cancer

MIT receives $90M from Ludwig Cancer Research to strengthen interdisciplinary approach to cancer research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News